Pancreatic carcinoma remains one of the leading cancer-related causes of death worldwide and is generally characterized by a dismal prognosis and limited potential for oncologic treatment. A rare subvariant of pancreatic cancer, undifferentiated carcinoma with osteoclast-like giant cells (UCOGC), has an unpredictable prognosis according to many previous studies, with unexpectedly long survival in individual cases. In this study, we collected, retrospectively, 13 cases of well-documented UCOGCs and performed immunohistochemistry focused on the expression of the programmed death-ligand 1 (PD-L1) and several other potential therapeutic and predictive markers (PanTRK, p53, MSH2, PMS2, and the number of tumor-infiltrating lymphocytes), to explore their correlation with the follow-up of the patients. As a control group, we examined 24 cases of conventional pancreatic ductal adenocarcinoma (PDAC). In our results, PanTRK was negative in all 24 cases. P53 did not show any significant differences between UCOGCs and PDACs, and the entire cohort was MSH2, MLH1, PMS2, and MSH6 positive. Significant differences were present in the analysis of PD-L1: UCOGCs were found to express PD-L1 significantly more frequently and have a higher number of tumor-infiltrating lymphocytes than PDAC. The expression of PD-L1 was related to significantly shorter survival in patients with UCOGC and in the entire cohort. Patients with PD-L1 negative UCOGCs displayed surprisingly long survival in comparison to PD-L1 positive UCOGCs and PDACs (both PD-L1+ and PD-L1-). We compared our results with previously published data, and, after statistical analysis, we were able to identify PD-L1 as an effective prognostic marker of UCOGC and suggest a strong need for a clinical trial of immune checkpoint immunotherapy in patients with advanced PD-L1 positive UCOGC.

Clinical and Transplant Pathology Centre Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Anesthesiology and Intensive Care 3rd Faculty of Medicine Charles University and Kralovske Vinohrady University Hospital Prague Czech Republic

Department of General Surgery 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Thomayer Hospital Prague Czech Republic

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Czech Republic

Virchows Arch. 2021 Mar;478(3):595-596. doi: 10.1007/s00428-021-03021-9. PubMed

Zobrazit více v PubMed

Muraki T, Reid MD, Bastruk O, Jang KT, Bedolla G, Bagci P, Mittal P, Bahar M, Katabi N, Bandyopadhyay S, Sarmiento JM, Krasinskas A, Klimstra DS, Adsay V (2016) Undifferentiated carcinoma with osteoclastic giant cells of the pancreas: clinicopathological analysis of 38 cases highlights a more protracted clinical course than currently appreciated. Am J Surg Pathol 40(9):1203–1216 PubMed DOI PMC

Sommers SC, Meissner WA (1954) Unusual carcinomas of the pancreas. AMA Arch Pathol 58:101–111 PubMed

Rosai J (1968) Carcinoma of pancreas simulating giant cell tumor of bone. Electron-microscopic evidence of its acinar cell origin. Cancer. 22:333–344 PubMed DOI

Molberg KH, Heffess C, Delgado R, Albores-Saavedra J (1998) Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas and periampullary region. Cancer. 82(7):1279–1287 PubMed DOI

Paal E, Thompson LD, Frommelt RA, Przygodzki RM, Heffess CS (2001) A clinicopathologic and immunohistochemical study of 35 anaplastic carcinomas of the pancreas with a review of the literature. Ann Diagn Pathol 5(3):129–140 PubMed DOI

Lamps LW (2018) Pancreas and ampullary region. In: Goldblum JR, Lamps LW, McKenney JK, Myers JL (eds) Rosai and Ackerman's surgical pathology. Elsevier, Philadelphia, pp 900–902

Hruban RH, Adsay NV, Esposito I, Fukushima N, Furukawa T, Klöppel G, Maitra A, Notohara K, Offerhaus GJA, Ohike N, Pitman MB, Zamboni G. Pancreatic ductal adenocarcinoma. In: WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. Pp. 329–330

Westra WH, Sturm P, Drillenburg P, Choti MA, Klimstra DS, Albores-Saavedra J, Montag A, Offerhaus GJ, Hruban RH (1998) K-ras oncogene mutations in osteoclast-like giant cell tumors of the pancreas and liver: genetic evidence to support origin from the duct epithelium. Am J Surg Pathol 22:1247–1254 PubMed DOI

Posen JA (1981) Giant cell tumor of the pancreas of the osteoclastic type associated with a mucous secreting cystadenocarcinoma. Hum Pathol 12:944–947 PubMed DOI

Lane RB Jr, Sangueza OP (1997) Anaplastic carcinoma occurring in association with a mucinous cystic neoplasm of the pancreas. Arch Pathol Lab Med 121:533–535 PubMed

Hirano H, Morita K, Tachibana S, Okimura A, Fujisawa T, Ouchi S, Nakasho K, Ueyama S, Nishigami T, Terada N (2008) Undifferentiated (anaplastic) carcinoma with osteoclast like giant cells arising in a mucinous cystic neoplasm of the pancreas. Pathol Int 58:383–389 PubMed DOI

Fujii K, Nitta T, Kawasaki H, Kataoka J, Tominaga T, Inoue Y, Kadota E, Ishibashi T, Uchiyama K (2016) Anaplastic carcinoma of the pancreas arising in an intraductal papillary mucinous neoplasm: a case report. Mol Clin Oncol 4(1):39–42 PubMed DOI

Chiarelli M, Guttadauro A, Gerosa M, Marando A, Gabrielli F, De Simone M, Cioffi U (2015) An indeterminate mucin-producing cystic neoplasm containing an undifferentiated carcinoma with osteoclast-like giant cells: a case report of a rare association of pancreatic tumors. BMC Gastroenterol 15:161 PubMed DOI PMC

Jang KT, Park SM, Basturk O, Bagci P, Bandyopadhyay S, Stelow EB, Walters DM, Choi DW, Choi SH, Heo JS, Sarmiento JM, Reid MD, Adsay V (2015) Clinicopathologic characteristics of 29 invasive carcinomas arising in 178 pancreatic mucinous cystic neoplasms with ovarian-type stroma: implications for management and prognosis. Am J Surg Pathol 39:179–187 PubMed DOI PMC

Sekulic M, Gilles S, Amin K, Stewart J (2016) Undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: a series of 5 cases with clinicopathologic correlation and cytomorphologic characterization. J Am Soc Cytopathol 5(6):321–330 PubMed DOI

Luchini C, Pea A, Lionheart G, Mafficini A, Nottegar A, Veronese N, Chianchiano P, Brosens LAA, Noë M, Offerhaus GJA, Yonescu R, Ning Y, Malleo G, Riva G, Piccoli P, Cataldo I, Capelli P, Zamboni G, Scarpa A, Wood LD (2017) Pancreatic undifferentiated carcinoma with osteoclast-like giant cells is genetically similar to, but clinically distinct from, conventional ductal adenocarcinoma. J Pathol 243(2):148–154 PubMed DOI PMC

Dworak O, Wittekind C, Koerfgen HP, Gall FP (1993) Osteoclastic giant cell tumor of the pancreas. An immunohistological study and review of the literature. Pathol Res Pract 189:228–234 PubMed DOI

Reid MD, Muraki T, HooKim K, Memis B, Graham RP, Allende D, Shi J, Schaeffer DF, Singh R, Basturk O, Adsay V (2017) Cytologic features and clinical implications of undifferentiated carcinoma with osteoclastic giant cells of the pancreas: an analysis of 15 cases. Cancer Cytopathol 125(7):563–575 PubMed DOI

Lehrke HD, Graham RP, McWilliams RR, Lam-Himlin DM, Smyrk TC, Jenkins S, Dong H, Zhang L (2017) Undifferentiated pancreatic carcinomas display enrichment for frequency and extent of PD-L1 expression by tumor cells. Am J Clin Pathol 148(5):441–449 PubMed DOI

Luchini C, Cros J, Pea A, Pilati C, Veronese N, Rusev B, Capelli P, Mafficini A, Nottegar A, Brosens LAA, Noë M, Offerhaus GJA, Chianchiano P, Riva G, Piccoli P, Parolini C, Malleo G, Lawlor RT, Corbo V, Sperandio N, Barbareschi M, Fassan M, Cheng L, Wood LD, Scarpa A (2018) PD-1, PD-L1 and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Hum Pathol 81:157–165 PubMed DOI

Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 372:311–319 PubMed DOI

Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, Dronca R, Gangadhar TC, Patnaik A, Zarour H, Joshua AM, Gergich K, Elassaiss-Schaap J, Algazi A, Mateus C, Boasberg P, Tumeh PC, Chmielowski B, Ebbinghaus SW, Li XN, Kang SP, Ribas A (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369:134–144 PubMed DOI PMC

Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbé C, Charles J, Mihalcioiu C, Chiarion-Sileni V, Mauch C, Cognetti F, Arance A, Schmidt H, Schadendorf D, Gogas H, Lundgren-Eriksson L, Horak C, Sharkey B, Waxman IM, Atkinson V, Ascierto PA (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330 DOI

Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465 PubMed DOI PMC

Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ (2014) MPDL3280A (anti-PD-L1)treatment Leeds to clinical activity in metastatic bladder cancer. Nature. 515:558–562 PubMed DOI

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372(26):2509–2520 PubMed DOI PMC

Dudley JC, Lin MT, Le DT, Eshleman JR (2016) Microsatellite instability as a biomarker for PD-1 blockade. Clin Cancer Res 22(4):813–820 PubMed DOI

Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK et al (2017) Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357(6349):409–413 PubMed DOI PMC

Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, Nagtegaal ID, Palmqvist R, Masucci GV, Botti G, Tatangelo F, Delrio P, Maio M, Laghi L, Grizzi F, Asslaber M, D'Arrigo C, Vidal-Vanaclocha F, Zavadova E, Chouchane L, Ohashi PS, Hafezi-Bakhtiari S, Wouters BG, Roehrl M, Nguyen L, Kawakami Y, Hazama S, Okuno K, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Wang Y, Kopetz S, Sinicrope FA, Scripcariu V, Ascierto PA, Marincola FM, Fox BA, Pagès F (2014) Towards the introduction of the Immunoscore in the classification of the malignant tumours. J Pathol 232(2):199–209 PubMed DOI

R Core Team (2019). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/ .

Therneau T (2015). A Package for Survival Analysis in R. version 3.1–7, https://CRAN.R-project.org/package=survival

Gao HL, Liu L, Qi ZH, Xu HX, Wang WQ, Wu CT, Zhang SR, Xu JZ, Ni QX, Yu XJ (2018) The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: a meta-analysis. Hepatobiliary Pancreat Dis Int 17(2):95–100 PubMed DOI

Hu Y, Chen W, Yan Z, Ma J, Zhu F, Huo J (2019) Prognostic value of PD-L1 expression in patients with pancreatic cancer: a PRISMA-compliant meta-analysis. Medicine (Baltimore) 98(3):e14006 DOI

Gocke CD, Dabbs DJ, Benko FA, Silverman JF (1997) KRAS oncogene mutations suggest a common histogenetic origin for pleomorphic giant cell tumor of the pancreas, osteoclastoma of the pancreas, and pancreatic duct adenocarcinoma. Hum Pathol 28(1):80–83 PubMed DOI

O’Reilly EM, Hechtkam JF (2019) Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. Ann Oncol 30(Suppl 8):viii36–viii40 PubMed DOI PMC

Pishvaian MJ, Rolfo CD, Liu SV, Multani PS, Maneval EC, Garrido-Laguna I (2018) Clinical benefit of entrectinib for patients with metastatic pancreatic cancer who harbor NTRK and ROS1 fusions. J Clin Oncol 36(4_suppl):521 DOI

Nara S, Shimada K, Kosuge T, Kanai Y, Hiraoka N (2008) Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary mucinous neoplasms. Am J Surg Pathol 32(2):243–255 PubMed DOI

Oshikiri T, Miyamoto M, Shichinohe T, Suzuoki M, Hiraoka K, Nakakubo Y, Shinohara T, Itoh T, Kondo S, Katoh H (2003) Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response. J Surg Oncol 84:224–248 PubMed DOI

Fukunaga A, Miyamoto M, Cho Y, Murakami S, Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y, Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S, Katoh H (2004) CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 28:e26–e31 PubMed DOI

Goeppert B, Frauenshuh L, Zucknick M et al (2013) Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer. Br J Cancer 109:2665–2674 PubMed DOI PMC

Lohneis P, Sinn M, Bischoff S, Jühling A, Pelzer U, Wislocka L, Bahra M, Sinn BV, Denkert C, Oettle H, Bläker H, Riess H, Jöhrens K, Strifler JK (2017) Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. Eur J Cancer 83:290–301 PubMed DOI

Nejati R, Goldstein JB, Halperin DM, Wang H, Hejazi N, Rashid A, Katz MH, Lee JE, Fleming JB, Rodriguez-Canales J, Blando J, Wistuba II, Maitra A, Wolff RA, Varadhachary GR, Wang H (2017) Prognostic significance of tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma treated with neoadjuvant chemotherapy. Pancreas. 46:1180–1187 PubMed DOI PMC

Hamza A, Khan U, Khurram MS, Abraham R, Mazzara P, Hadid T, Kafri Z (2019) Prognostic utility of tumor-infiltrating lymphocytes in noncolorectal gastrointestinal malignancies. Int J Surg Pathol 27(3):263–267 PubMed DOI

A current knowledge of the undifferentiated carcinoma of the pancreas with osteoclast-like giant cells: a narrative review

Expression of Selected miRNAs in Undifferentiated Carcinoma with Osteoclast-like Giant Cells (UCOGC) of the Pancreas: Comparison with Poorly Differentiated Pancreatic Ductal Adenocarcinoma

Undifferentiated Carcinoma with Osteoclast-like Giant Cells of the Pancreas: Molecular Genetic Analysis of 13 Cases

Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer